[go: up one dir, main page]

AR029619A1 - VACCINE - Google Patents

VACCINE

Info

Publication number
AR029619A1
AR029619A1 ARP000100821A ARP000100821A AR029619A1 AR 029619 A1 AR029619 A1 AR 029619A1 AR P000100821 A ARP000100821 A AR P000100821A AR P000100821 A ARP000100821 A AR P000100821A AR 029619 A1 AR029619 A1 AR 029619A1
Authority
AR
Argentina
Prior art keywords
medicine
refers
ige
new
regions
Prior art date
Application number
ARP000100821A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biolog, Peptide Therapeutics Ltd filed Critical Smithkline Beecham Biolog
Publication of AR029619A1 publication Critical patent/AR029619A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a proporcionar nuevos medicamentos para el tratamiento, prevencion o alivio de enfermedades alérgicas. En particular, los nuevos medicamentos son epítopos o mimotopos derivados de los dominios Ce3 y Ce4 de IgE. Estas nuevas regiones pueden ser la diana de inmunoprofilaxis o inmunoterapia activa o pasiva. La presente se refiere además a procedimientos para producir los medicamentos, a composiciones farmacéuticas que contienen los mismos y a su uso en medicina. También constituyen un aspecto de la presente ligandos, en especial anticuerpos monoclonales, que pueden unirse a las regiones de IgE de la invencion, y su uso en medicina como inmunoterapia pasiva.This refers to providing new medications for the treatment, prevention or relief of allergic diseases. In particular, the new drugs are epitopes or mimotopes derived from the Ce3 and Ce4 domains of IgE. These new regions may be the target of immunoprophylaxis or active or passive immunotherapy. This also refers to procedures for producing the medicines, pharmaceutical compositions containing them and their use in medicine. They also constitute an aspect of the present ligands, especially monoclonal antibodies, which can bind to the IgE regions of the invention, and their use in medicine as passive immunotherapy.

ARP000100821A 1999-02-25 2000-02-25 VACCINE AR029619A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine

Publications (1)

Publication Number Publication Date
AR029619A1 true AR029619A1 (en) 2003-07-10

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100821A AR029619A1 (en) 1999-02-25 2000-02-25 VACCINE

Country Status (18)

Country Link
EP (1) EP1155038A1 (en)
JP (1) JP2002537403A (en)
KR (1) KR20020007314A (en)
CN (1) CN1520423A (en)
AR (1) AR029619A1 (en)
AU (1) AU3281100A (en)
CA (1) CA2363641A1 (en)
CO (1) CO5231139A1 (en)
CZ (1) CZ20013081A3 (en)
HK (1) HK1043134A1 (en)
HU (1) HUP0105490A3 (en)
IL (1) IL145025A0 (en)
MX (1) MXPA01008612A (en)
NO (1) NO20014131L (en)
NZ (1) NZ513680A (en)
PL (1) PL350992A1 (en)
TR (1) TR200102493T2 (en)
WO (1) WO2000050461A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2206701A (en) * 1999-12-21 2001-07-03 Acambis Research Limited A reversible linkage technology for controlled conjugation
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP2003047482A (en) * 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
CN1599623B (en) 2001-09-14 2011-05-11 赛托斯生物技术公司 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CA2489410C (en) 2002-07-17 2015-01-13 Cytos Biotechnology Ag Molecular antigen arrays
CN100518823C (en) 2002-07-18 2009-07-29 赛托斯生物技术公司 Hapten-carrier conjugates and uses thereof
US7279165B2 (en) 2002-07-19 2007-10-09 Cytos Biotechnology Ag Amyloid β1-6 antigen arrays
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP1605972A2 (en) 2003-03-26 2005-12-21 Cytos Biotechnology AG Hiv-peptide-carrier-conjugates
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2624081C (en) 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
NZ569741A (en) 2005-12-14 2012-02-24 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007144150A1 (en) 2006-06-12 2007-12-21 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
EP2865389A1 (en) * 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
JP5918851B2 (en) * 2012-06-18 2016-05-18 日本全薬工業株式会社 IgE peptide vaccine
US20210055305A1 (en) * 2018-04-06 2021-02-25 Slsbio Co., Ltd. Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments
WO2024155914A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Hair care appliance with powered attachment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (en) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd Peptide having anti-allergic activity
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
SI0885244T2 (en) * 1996-03-01 2008-10-31 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
JP2002537403A (en) 2002-11-05
HUP0105490A3 (en) 2002-05-28
EP1155038A1 (en) 2001-11-21
KR20020007314A (en) 2002-01-26
NO20014131L (en) 2001-10-02
TR200102493T2 (en) 2002-02-21
PL350992A1 (en) 2003-02-24
NZ513680A (en) 2001-09-28
MXPA01008612A (en) 2003-06-24
CO5231139A1 (en) 2002-12-27
CA2363641A1 (en) 2000-08-31
CZ20013081A3 (en) 2002-02-13
NO20014131D0 (en) 2001-08-24
AU3281100A (en) 2000-09-14
HUP0105490A2 (en) 2002-04-29
WO2000050461A1 (en) 2000-08-31
CN1520423A (en) 2004-08-11
IL145025A0 (en) 2002-06-30
HK1043134A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
AR029619A1 (en) VACCINE
Harrison et al. Research strategies to improve snakebite treatment: Challenges and progress
MA47313A (en) SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES
CR10244A (en) TUMOR THERAPY WITH AN ANTIBODY AGAINST THE VASCULAR ENDOTELIAL GROWTH FACTOR AND AN ANTIBODY AGAINST THE HUMAN TYPE 2 EPITELIAL GROWTH FACTOR RECEIVER
ATE414534T1 (en) IMMUNOTHERAPEUTIC METHODS AND SYSTEMS
CR8698A (en) MONOCLONAL ANTIBODIES TO THE HEPATOCITE GROWTH FACTOR
EA200101064A1 (en) TREATMENT OF CANCER DISEASES THROUGH COMBINED INTRODUCTION OF A DOCETIXEL WITH RECOMBINANT HUMANIZED MONOCLONAL ANTI-HER2 ANTI-TITLES
AR069290A1 (en) MONOCLONAL ANTIBODIES THAT JOIN THE HGM -CSF (STIMULATING FACTOR OF THE COLONY OF GRANULOCITOS-MACROFAGOS) AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM
DK1684869T3 (en) Method of Therapy for B-Cell-Related Cancer Diseases
EA202191244A1 (en) NEW CYTOSTATIC CONJUGATES WITH INTEGRIN LIGANDS
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
MY205774A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
Sibaud et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series
ES2376564B1 (en) USE OF ANTIBODIES AGAINST NK1, NK2 AND / OR NK3 RECEPTORS, TO PRODUCE APOPTOSIS IN TUMOR CELLS AND TO MODIFY STRAMA, IMMUNITY AND INTRA AND PERITUMORAL VASCULARIZATION, AS TREATMENT OF CANCER.
CL2022003715A1 (en) Tubulysins and protein-tubulysin conjugates
AR045765A1 (en) MOLECULES OF UNION TO CD45 AND THERAPEUTIC USE
BR112023002301A2 (en) ANTIBODIES AGAINST ILT2 AND THEIR USE
EA201500506A1 (en) Conjugates and small molecules interacting with the CD16a receptor
RU2011130522A (en) MONOCLONAL ANTIBODY AGAINST HCV AS A MEDICINE FOR THE THERAPEUTIC TREATMENT AND PREVENTION OF HCV INFECTIONS
AR029336A1 (en) USEFUL PEPTIDES TO PREPARE MEDICINES FOR THE TREATMENT, PREVENTION OR IMPROVEMENT OF ALLERGIC STATES, IMMUNOGENS, EPITHOPES AND MIMOTOPES, VACCINES, LIGENDS, PHARMACEUTICAL COMPOSITIONS; USE OF THE PEPTIDES, OF THE LIGANDS IN THE PREPARATION OF MEDICINES; PROCESS TO PREPARE VACCINES AND PR
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
EA202192488A1 (en) ANTIBODIES AGAINST TSG-6 AND THEIR APPLICATIONS
BR112023000455A2 (en) TREATMENT OF INFLAMMATORY DISEASE USING ANTI-TISSUE FACTOR ANTIBODIES
RU2015147913A (en) ANTIBODY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR
WO2002034288A8 (en) Vaccine for treating allergy

Legal Events

Date Code Title Description
FA Abandonment or withdrawal